# AstraZeneca (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/astrazeneca-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 44.5 |
| Citations | 1,310,146 |
| City | Wilmington |
| Country | US |
| Description | AstraZeneca (United States) is a research organisation in Wilmington, US. OpenAlex records 11,565 works and 1,310,146 citations for it. 3,279 researchers list it as their most recent affiliation. |
| Homepage | http://www.astrazeneca-us.com/home/ |
| OpenAlex ID | https://openalex.org/I4210150756 |
| Region | Delaware |
| Researchers | 3,279 |
| ROR ID | https://ror.org/043cec594 |
| Type | company |
| Works | 11,565 |

## University papers

Showing 12 of 30.

- [Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach](https://scholariq.org/papers/decoding-tumour-phenotype-by-noninvasive-imaging-using-a-quantitative-radiomics/)
- [Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)](https://scholariq.org/papers/definition-and-classification-of-chronic-kidney-disease-a-position-statement/)
- [Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden](https://scholariq.org/papers/analysis-of-100-000-human-cancer-genomes-reveals-the-landscape-of-tumor/)
- [Olaparib for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/olaparib-for-metastatic-castration-resistant-prostate-cancer/)
- [Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M](https://scholariq.org/papers/acquired-egfr-c797s-mutation-mediates-resistance-to-azd9291-in-non-small-cell/)
- [Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes](https://scholariq.org/papers/chronic-kidney-disease-as-a-global-public-health-problem-approaches-and/)
- [Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/association-between-plasma-genotyping-and-outcomes-of-treatment-with-osimertinib/)
- [Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors](https://scholariq.org/papers/activation-of-met-via-diverse-exon-14-splicing-alterations-occurs-in-multiple/)
- [Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation](https://scholariq.org/papers/acquired-resistance-to-egfr-tyrosine-kinase-inhibitors-in-egfr-mutant-lung/)
- [Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer](https://scholariq.org/papers/final-results-from-prime-randomized-phase-iii-study-of-panitumumab-with-folfox4/)
- [Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial](https://scholariq.org/papers/olaparib-combined-with-chemotherapy-for-recurrent-platinum-sensitive-ovarian/)
- [Catastrophic Antiphospholipid Syndrome: Clinical and Laboratory Features of 50 Patients](https://scholariq.org/papers/catastrophic-antiphospholipid-syndrome-clinical-and-laboratory-features-of-50/)

## University researchers

- [Kevin Daly](https://scholariq.org/researchers/kevin-daly/)

## University top topics

Showing 8 of 25.

- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Chronic Obstructive Pulmonary Disease (COPD) Research](https://scholariq.org/topics/chronic-obstructive-pulmonary-disease-copd-research/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.